Roger L. Priore
About
In The Last Decade
Roger L. Priore
55 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 141
- Pathology and Forensic Medicine 628
- Oncology 505
- Public Health, Environmental and Occupational Health 401
- Molecular Biology 381
- Cancer Research 226
Countries citing papers authored by Roger L. Priore
This map shows the geographic impact of Roger L. Priore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger L. Priore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger L. Priore more than expected).
Fields of papers citing papers by Roger L. Priore
This network shows the impact of papers produced by Roger L. Priore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger L. Priore. The network helps show where Roger L. Priore may publish in the future.
Co-authorship network of co-authors of Roger L. Priore
This figure shows the co-authorship network connecting the top 25 collaborators of Roger L. Priore. A scholar is included among the top collaborators of Roger L. Priore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger L. Priore. Roger L. Priore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 24 | |
| 2 | 19 | |
| 3 | 26 | |
| 4 | 3 | |
| 5 | 77 | |
| 6 | 167 | |
| 7 | 8 | |
| 8 | 6 | |
| 9 | 14 | |
| 10 | 65 | |
| 11 | 107 | |
| 12 | 33 | |
| 13 | 163 | |
| 14 | 4 | |
| 15 | Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin. | 3 |
| 16 | 11 | |
| 17 | Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma. | 5 |
| 18 | 7 | |
| 19 | 7 | |
| 20 | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.